文献速递银屑病与炎症性皮肤病

司库奇尤单抗12周疗效不受既往系统治疗影响:六项随机试验事后分析

Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2021-02-09

该事后分析汇总六项随机对照试验,评估司库奇尤单抗300mg治疗中重度银屑病12周的疗效与安全性。结果显示,无论既往是否使用生物制剂或非生物系统治疗,司库奇尤单抗均显著优于安慰剂,且在许多结局上优于乌司奴单抗和依那西普;安全性与其他试验一致。

要点

  • 司库奇尤单抗12周疗效在所有亚组中均显著优于安慰剂。
  • 既往非生物系统治疗对司库奇尤单抗疗效影响可忽略。
  • 生物制剂初治患者对司库奇尤单抗的反应优于经治患者。

核心结论

  • 司库奇尤单抗300mg治疗12周对中重度银屑病患者 consistently 优于安慰剂、依那西普和乌司奴单抗,无论既往是否暴露于生物制剂或非生物系统治疗。
  • 司库奇尤单抗的安全性特征与依那西普和乌司奴单抗相当。

研究设计与样本

  • 六项随机对照试验的事后分析,比较司库奇尤单抗与安慰剂、乌司奴单抗或依那西普治疗12周。
  • 司库奇尤单抗vs安慰剂和vs乌司奴单抗的数据进行荟萃分析,vs依那西普来自单一项随机对照试验。
  • 评估四个亚组:非生物系统治疗和生物制剂均初治;非生物系统治疗经治但生物制剂初治;非生物系统治疗初治但生物制剂经治;非生物系统治疗和生物制剂均经治。

主要发现

  • 在所有亚组中,司库奇尤单抗在全部测量结局上均显著优于安慰剂。
  • 生物制剂初治患者的司库奇尤单抗应答更高,而既往非生物系统治疗对治疗应答影响可忽略。
  • 司库奇尤单抗在许多结局上优于乌司奴单抗和依那西普,生物制剂初治患者的差异大于生物制剂经治患者。
  • 安全性结果与各单项临床试验结果一致。

关键数值与推荐

  • 结局包括研究者全球评估(IGA)评分、银屑病面积和严重程度指数(PASI)绝对应答、PASI 75、PASI 90、PASI 100应答和皮肤病生活质量指数(DLQI)。
  • 安全性也进行了评估。

临床怎么用

  • 对于中重度银屑病患者,无论既往是否使用过生物制剂或非生物系统治疗,司库奇尤单抗300mg治疗12周均可考虑作为有效选择。
  • 生物制剂初治患者可能从司库奇尤单抗获得更高应答,但生物制剂经治患者仍可获益。
  • 既往非生物系统治疗史不应影响司库奇尤单抗的选用决策。

局限性

  • 为事后分析,证据等级低于预设主要分析。
  • 司库奇尤单抗与依那西普的比较仅来自单一项随机对照试验。
  • 评估时间点为12周,长期疗效未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy of biologic therapies is greater among biologic-naïve vs. biologic-experienced psoriasis patients. However, little is known as to whether prior use of other systemic therapies impacts secukinumab efficacy in patients with moderate-to-severe psoriasis. OBJECTIVE: To investigate the impact of prior exposure to systemic therapies upon the efficacy and safety of secukinumab 300 mg for moderate-to-severe psoriasis. METHODS: Post hoc analysis of six randomised controlled trials (RCTs) comparing secukinumab with placebo, ustekinumab or etanercept at 12 weeks of treatment. Data comparing secukinumab with placebo and ustekinumab were meta-analysed, while comparisons between secukinumab and etanercept were from a single RCT. Four subgroups of patients were assessed: (i) naïve to non-biologic systemics (NBS) and biologics; (ii) exposed to NBS but naïve to biologics; (iii) naïve to NBS but exposed to biologics; and (iv) exposed to NBS and biologics. Outcomes of interest included the following: investigator's global assessment (IGA) score, absolute psoriasis area and severity index (PASI) response, PASI 75, PASI 90 and PASI 100 responses, and dermatology life quality index (DLQI). Safety was also assessed. RESULTS: One thousand three hundred and eighty-three patients were included in the secukinumab vs. placebo meta-analysis: 1776 in the secukinumab vs. ustekinumab meta-analysis and 653 in the within-trial analyses of secukinumab vs. etanercept. For all subgroups, secukinumab was significantly more efficacious than placebo for all outcomes measured. Secukinumab generated greater responses in biologic-naïve patients, while prior NBS had a negligible impact on treatment response. Furthermore, secukinumab was more efficacious than both ustekinumab and etanercept on many outcomes, with an even greater difference for biologic-naïve than biologic-exposed patients. Safety results were consistent with individual clinical trial results. CONCLUSIONS: Twelve-week treatment with secukinumab 300 mg is consistently more efficacious than placebo, etanercept and ustekinumab in patients with moderate-to-severe psoriasis, regardless of prior exposure to biologics or NBS. Secukinumab had a comparable safety profile to both etanercept and ustekinumab.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Hampton P, Halliday A, Aassi M, et al. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials. J Eur Acad Dermatol Venereol. 2021. PMID: 33030755. doi:10.1111/jdv.16982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。